News

Valneva announced that it has completed recruitment of the initial cohort of elderly participants in Valneva’s Phase 3 trial, VLA2001-304, of its…

Read more

Stefan Ameres obtained his Master’s degree from the University of Erlangen-Nuremberg (Germany) and his PhD from the University of Vienna. After…

Read more

Today, Austria’s Federal Minister of Health Wolfgang Mückstein visited the Vienna BioCenter. Through presentations and a campus tour, the…

Read more

In order to exchange genetic material between parental chromosomes during meiosis, cells need to introduce DNA double strand breaks (DSBs) that are…

Read more

Valneva commenced rolling submission, for initial approval of its COVID-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products…

Read more

The Vienna BioCenter Summer School offers undergraduate and masters students from around the world a unique opportunity to conduct a two-month…

Read more

Piwi-interacting RNAs (piRNAs) are essential to repress transposable elements in the animal germline. In the nematode worm C. elegans, piRNA…

Read more

The protein kinase Akt is activated in the PI3K pathway by a combination of signaling phospholipids and phosphorylation by upstream protein kinases.…

Read more

Valneva announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.…

Read more

The PhD student and dedicated science communicator Adrià Nogales Moral (Köhler lab) has written a children´s book about tardigrades, runs his own…

Read more

Valneva announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was…

Read more

AFFiRiS AG announced that AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is…

Read more